{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:16:53Z","timestamp":1783192613134,"version":"3.54.6"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52403183"],"award-info":[{"award-number":["52403183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2023ZYGXZR047"],"award-info":[{"award-number":["2023ZYGXZR047"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2025A1515011561"],"award-info":[{"award-number":["2025A1515011561"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2024A04J3721"],"award-info":[{"award-number":["2024A04J3721"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jconrel.2026.114994","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:54:49Z","timestamp":1778543689000},"page":"114994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PSMA-directed nanoprobe enabling precision imaging and MR-guided chemoradiotherapy in prostate cancer"],"prefix":"10.1016","volume":"395","author":[{"given":"Bochang","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhinan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yejiao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darya R.","family":"Akhmetova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei A.","family":"Shipilovskikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghua","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Timin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114994_bb0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2026.114994_bb0010","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2026.114994_bb0015","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ijrobp.2024.12.011","article-title":"Evolution of image guidance and adaptive radiation therapy for localized prostate Cancer","volume":"122","author":"Patel","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jconrel.2026.114994_bb0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging\u2013guided vs computed tomography\u2013guided stereotactic body radiotherapy for Prostate Cancer: the MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10462-025-11378-5","article-title":"Heuristics for the direct aperture optimisation in intensity modulated radiotion therapy: a systematic literature review","volume":"59","author":"Moyano","year":"2025","journal-title":"Artif. Intell. Rev."},{"key":"10.1016\/j.jconrel.2026.114994_bb0030","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/s41567-025-02993-8","article-title":"Image-guided treatment of mouse tumours with radioactive ion beams","volume":"21","author":"Boscolo","year":"2025","journal-title":"Nat. Phys."},{"key":"10.1016\/j.jconrel.2026.114994_bb0035","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2025.03.016","article-title":"Stereotactic body radiation therapy alone or in combination with immunotherapy in kidney Cancer: a systematic review","volume":"88","author":"Sundahl","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0040","doi-asserted-by":"crossref","first-page":"e18020","DOI":"10.1200\/JCO.2021.39.15_suppl.e18020","article-title":"Survival results of phase I dose escalation of stereotactic body radiation therapy and concurrent cisplatin for re-irradiation of unresectable, recurrent head and neck squamous cell carcinoma","volume":"39","author":"Echevarria","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0045","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.prnil.2024.09.004","article-title":"Comparing the efficacy of tadalafil and tamsulosin for managing erectile dysfunction and lower urinary tract symptoms in prostate brachytherapy patients: a prospective study","volume":"12","author":"Hayakawa","year":"2024","journal-title":"Prostate Int."},{"key":"10.1016\/j.jconrel.2026.114994_bb0050","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/jama.2025.7045","article-title":"Lower urinary tract symptoms in men: a review","volume":"334","author":"Wei","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2026.114994_bb0055","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2025.05.038","article-title":"Magnetic resonance imaging\u2013based biopsy strategies in prostate Cancer screening: a systematic review","volume":"88","author":"Schoots","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0060","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3322\/caac.70020","article-title":"The contemporary management of prostate cancer","volume":"75","author":"Chakrabarti","year":"2025","journal-title":"CA-Cancer J Clin"},{"key":"10.1016\/j.jconrel.2026.114994_bb0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0140-6736(23)02476-5","article-title":"Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study","volume":"403","author":"Mann","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.114994_bb0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.semradonc.2023.10.001","article-title":"MRI-guided radiotherapy for prostate Cancer: seeing is believing","volume":"34","author":"Westley","year":"2024","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0075","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2026.114994_bb0080","doi-asserted-by":"crossref","first-page":"17097","DOI":"10.1021\/jacs.1c07377","article-title":"Magnetic resonance imaging of PSMA-positive prostate Cancer by a targeted and activatable Gd(III) MR contrast agent","volume":"143","author":"Li","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114994_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2024.216101","article-title":"Targeted delivery of nano-radiosensitizers for tumor radiotherapy","volume":"518","author":"Shi","year":"2024","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.jconrel.2026.114994_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.70035","article-title":"Mechanisms of tumor Radiosensitization: a perspective of Nano-radiotherapy","volume":"17","author":"Zhou","year":"2025","journal-title":"Wires Nanomed Nanobi"},{"key":"10.1016\/j.jconrel.2026.114994_bb0095","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.1021\/acs.nanolett.0c02487","article-title":"Targeted radiosensitizers for MR-guided radiation therapy of prostate cancer","volume":"20","author":"Luo","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2026.114994_bb0100","doi-asserted-by":"crossref","first-page":"8119","DOI":"10.1039\/C9SC02290B","article-title":"3-6 prostate-specific membrane antigen targeted gold nanoparticles for prostate cancer radiotherapy: does size matter for targeted particles?","volume":"10","author":"Luo","year":"2019","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2026.114994_bb0105","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0110","doi-asserted-by":"crossref","first-page":"e16520","DOI":"10.1200\/JCO.2016.34.15_suppl.e16520","article-title":"Management of non metastatic castrate resistant prostate cancer (NM-CRPC), results of a UK wide national survey","volume":"34","author":"Latif","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0115","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1158\/1538-7445.AM2025-3933","article-title":"Abstract 3933: Modeling treatment na\u00efve and castration-resistant metastatic prostate cancer in genetically engineered mouse models","volume":"85","author":"Turgeon","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114994_bb0120","article-title":"Nonpersistent nanoarchitectures enhance concurrent chemoradiotherapy in an immunocompetent orthotopic model of HPV+ head\/neck carcinoma","volume":"36","author":"Gonnelli","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114994_bb0125","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.1200\/JCO.2020.38.15_suppl.6031","article-title":"Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer","volume":"38","author":"Kou","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0130","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.7150\/ijbs.15438","article-title":"A review of neoadjuvant chemoradiotherapy for locally advanced rectal Cancer","volume":"12","author":"Li","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.jconrel.2026.114994_bb0135","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2015.63.9393","article-title":"Consolidation chemotherapy after concurrent chemoradiotherapy in patients with stage III non\u2013small-cell lung Cancer","volume":"34","author":"Kim","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0140","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2023.04.024","article-title":"Androgen deprivation and radiotherapy with or without docetaxel for localized high-risk prostate cancer: long-term follow-up from the randomized NRG oncology RTOG 0521 trial","volume":"84","author":"Sartor","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0145","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0150","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2026.114994_bb0155","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1200\/JCO.2025.43.16_suppl.5511","article-title":"Primary results of a phase 2 study of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer","volume":"43","author":"Yeku","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2023.215439","article-title":"Oxaliplatin and its derivatives \u2013 An overview","volume":"497","author":"O'Dowd","year":"2023","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.jconrel.2026.114994_bb0165","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1021\/cr068207j","article-title":"Direct cellular responses to platinum-induced DNA damage","volume":"107","author":"Jung","year":"2007","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2026.114994_bb0170","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1039\/C8CS00641E","article-title":"Transition metal compounds as cancer radiosensitizers","volume":"48","author":"Gill","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2026.114994_bb0175","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4939-7741-3_2","article-title":"Multifunctional self-assembling peptide-based nanostructures for targeted intracellular delivery: design, physicochemical characterization, and biological assessment","author":"Shi","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0180","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1021\/acsnano.8b03476","article-title":"Tailoring platinum(IV) amphiphiles for self-targeting all-in-one assemblies as precise multimodal Theranostic nanomedicine","volume":"12","author":"He","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114994_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121793","article-title":"2-3 self-targeting platinum(IV) amphiphilic prodrug nano-assembly as radiosensitizer for synergistic and safe chemoradiotherapy of hepatocellular carcinoma","volume":"289","author":"Xiao","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.114994_bb0190","article-title":"Reactive cysteines in proteins are the dominant reductants for platinum(IV) prodrug activation in live cells","volume":"64","author":"Chen","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2026.114994_bb0195","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1039\/D4QI00459K","article-title":"Advances in technical strategies for monitoring the reduction of platinum(iv) complexes","volume":"11","author":"Chen","year":"2024","journal-title":"Inorg. Chem. Front."},{"key":"10.1016\/j.jconrel.2026.114994_bb0200","doi-asserted-by":"crossref","first-page":"11676","DOI":"10.1021\/acs.inorgchem.0c01541","article-title":"Stability, reduction, and cytotoxicity of platinum(IV) anticancer prodrugs bearing carbamate axial ligands: comparison with their carboxylate analogues","volume":"59","author":"Chen","year":"2020","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.jconrel.2026.114994_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314511","article-title":"Recent advances in light-controlled activation of Pt(IV) prodrugs","volume":"23","author":"Spector","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114994_bb0210","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejpb.2021.04.025","article-title":"Recent advances in prodrug-based nanoparticle therapeutics","volume":"165","author":"Chen","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.114994_bb0215","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1021\/nn5070953","article-title":"High Relaxivity Gd(III)\u2013DNA gold Nanostars: investigation of shape effects on proton relaxation","volume":"9","author":"Rotz","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114994_bb0220","doi-asserted-by":"crossref","first-page":"26478","DOI":"10.1021\/acs.jmedchem.5c02762","article-title":"Highly inert Gd-DOTA-based contrast agents with a lipophilic side chain for hepatobiliary and vascular magnetic resonance imaging","volume":"68","author":"Xu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.114994_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2025.163263","article-title":"An amphiphilic lanthanide complexes-based liposome nanoprobe for dual-modal time-gated luminescence and magnetic resonance imaging of hypochlorous acid in vitro and in vivo","volume":"514","author":"Liu","year":"2025","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.jconrel.2026.114994_bb0230","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0235","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41585-025-01014-w","article-title":"Targeting the tumour cell surface in advanced prostate cancer","volume":"22","author":"Boixareu","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0240","doi-asserted-by":"crossref","first-page":"7640","DOI":"10.1038\/s41467-025-62999-x","article-title":"Bioinspired ruthenium-manganese-oxygen complex for biocatalytic and radiosensitization therapies to eradicate primary and metastatic tumors","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114994_bb0245","article-title":"Icaritin ameliorates cisplatin-induced mitochondrial metabolic dysfunction-associated nephrotoxicity and synergistically potentiates its antitumor efficacy","volume":"13","author":"Luo","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.114994_bb0250","article-title":"The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy","volume":"57","author":"Li","year":"2025","journal-title":"Ann. Med."},{"key":"10.1016\/j.jconrel.2026.114994_bb0255","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41422-019-0263-3","article-title":"The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression","volume":"30","author":"Lei","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.jconrel.2026.114994_bb0260","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/bs.acr.2021.03.008","article-title":"Cisplatin chemotherapy and renal function","volume":"152","author":"Zhang","year":"2021","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114994_bb0265","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1124\/jpet.124.002287","article-title":"Understanding cisplatin pharmacokinetics and Toxicodynamics to predict and prevent kidney injury","volume":"391","author":"Thompson","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2026.114994_bb0270","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q","article-title":"The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma","volume":"88","author":"Carlin","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2026.114994_bb0275","doi-asserted-by":"crossref","first-page":"482","DOI":"10.21037\/atm.2020.03.55","article-title":"Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study","volume":"8","author":"Huang","year":"2020","journal-title":"Ann. Transl. Med"},{"key":"10.1016\/j.jconrel.2026.114994_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309941","article-title":"Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients","volume":"19","author":"Lai","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2026.114994_bb0285","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41590-022-01289-w","article-title":"Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation","volume":"23","author":"Kennedy","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.114994_bb0290","doi-asserted-by":"crossref","first-page":"e2836","DOI":"10.1038\/cddis.2017.67","article-title":"Interferon-\u03b3 derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity","volume":"8","author":"Bhat","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2026.114994_bb0295","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon Signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.114994_bb0300","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc.2017.6","article-title":"Pre-metastatic niches: organ-specific homes for metastases","volume":"17","author":"Peinado","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.114994_bb0305","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning cold into hot: firing up the tumor microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jconrel.2026.114994_bb0310","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.jconrel.2026.114994_bb0315","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1039\/C9SC05937G","article-title":"Gd(III)\u2013Pt(IV) theranostic contrast agents for tandem MR imaging and chemotherapy","volume":"11","author":"Adams","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2026.114994_bb0320","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s13204-022-02507-5","article-title":"Specified iron oxide nanoparticles by PSMA-11 as a promising nanomolecular imaging probe for early detection of prostate cancer","volume":"12","author":"Ghorbani","year":"2022","journal-title":"Appl. Nanosci."},{"key":"10.1016\/j.jconrel.2026.114994_bb0325","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400289","article-title":"A dual action platinum(IV) complex with self-assembly property inhibits prostate cancer through mitochondrial stress pathway","volume":"19","author":"Nafees","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jconrel.2026.114994_bb0330","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1073\/pnas.1011379108","article-title":"Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo","volume":"108","author":"Dhar","year":"2011","journal-title":"PNAS"},{"key":"10.1016\/j.jconrel.2026.114994_bb0335","doi-asserted-by":"crossref","first-page":"17356","DOI":"10.1073\/pnas.0809154105","article-title":"Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA\u2013PEG nanoparticles","volume":"105","author":"Dhar","year":"2008","journal-title":"PNAS"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:02:32Z","timestamp":1783191752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926003974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":67,"alternative-id":["S0168365926003974"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114994","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA-directed nanoprobe enabling precision imaging and MR-guided chemoradiotherapy in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114994"}}